Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
30 May 2022 |
Main ID: |
NCT03914261 |
Date of registration:
|
11/04/2019 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Expanded Access to Risankizumab
|
Scientific title:
|
Expanded Access to Risankizumab |
Date of first enrolment:
|
July 1, 2019 |
Target sample size:
|
|
Recruitment status: |
No longer available |
URL:
|
https://clinicaltrials.gov/show/NCT03914261 |
Study type:
|
Expanded Access |
Study design:
|
|
Phase:
|
|
|
Countries of recruitment
|
Belgium
|
Israel
|
Spain
|
Switzerland
|
United States
| | | |
Contacts
|
Name:
|
AbbVie Inc. |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
AbbVie |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Ulcerative Colitis (UC)
|
Crohn's Disease
|
Intervention(s)
|
Drug: Risankizumab
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|